More on NKTR
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $68.36 |
|
|||
| Open | $68.00 | ||||
| 52 Wk High | $19.98 | ||||
| 52 Wk Low | $10.52 | ||||
| Day High | $68.60 | ||||
| Day Low | $68.00 | ||||
| P/E | N/A | ||||
| EPS | $-1.45 | ||||
| Volume | 38,365 | ||||
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nektar's atopic dermatitis drug data published in The Lancet
- Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
- TD Cowen Assumes Nektar Therapeutics (NKTR) at Buy
- JPMorgan Reinstates Nektar Therapeutics (NKTR) at Neutral
- Form 4 NEKTAR THERAPEUTICS For: Aug 18 Filed by: Zalevsky Jonathan
- Form 4 NEKTAR THERAPEUTICS For: Aug 18 Filed by: ROBIN HOWARD W
- Form 144 NEKTAR THERAPEUTICS Filed by: Zalevsky Jonathan
- Form 144 NEKTAR THERAPEUTICS Filed by: ROBIN HOWARD W
- Form SCHEDULE 13G/A NEKTAR THERAPEUTICS Filed by: Two Seas Capital LP
Entities mentioned with NKTR
- Earnings | View Related Stories »
- FDA | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Jefferies & Co | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
